Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III sirolimus trial for epileptic seizures in focal cortical dysplasia type II
jRCT2031230317Phase 3Completed
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Focal Onset Epilepsy, Focal Cortical Dysplasia Type 2 (FCD2) and hemimegalencephaly (HME) comparing Sirolimus with Placebo (2 arms). Started Sep 2023; status: completed.
02
Drugs
sirolimus
03
Conditions
Focal Onset EpilepsyFocal Cortical Dysplasia Type 2 (FCD2)hemimegalencephaly (HME)
Beyond the preview
Go deeper on jRCT2031230317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230317.